Welcoming Novelty in the Treatment of Coronary Artery Disease: FDA Approves the Use of Drug‐Coated Balloon for Angioplasty

BACKGROUND: Coronary artery disease (CAD) remains a leading cause of morbidity and mortality in the United States, with in-stent restenosis (ISR) posing a significant challenge following percutaneous coronary intervention (PCI). Drug-eluting stents (DES) have been widely used to mitigate ISR; however, until recently, no drug-coated balloon (DCB) catheter had been approved for use in the United States. The US Food and Drug Administration (FDA) has now approved AGENT DCB, a paclitaxel-coated balloon catheter, offering a novel approach to treating ISR. HYPOTHESIS: The approval of AGENT DCB represents a pivotal advancement in PCI, providing an effective alternative to traditional balloon angioplasty for ISR. METHODS: This article is an editorial review and does not involve original research, statistical analysis, or software-based evaluations. The findings and discussion are based on the results of the AGENT IDE trial and related literature on the efficacy of DCB catheters in the treatment of ISR. RESULTS: The AGENT IDE trial, a randomized, multicenter study involving 600 participants across 40 US sites, demonstrated that the paclitaxel-coated balloon group had a significantly lower target lesion failure rate at 12 months compared to the uncoated balloon group (17.9% vs. 28.6%, p = 0.003). The reduction was primarily driven by a lower incidence of target lesion revascularization (13.0% vs. 24.7%, p = 0.001) and myocardial infarction related to the target vessel (5.8% vs. 11.1%, p = 0.02). Additionally, no cases of stent thrombosis were observed in the DCB group compared to 3.2% in the control group (p = 0.001), reinforcing the device's safety and efficacy. CONCLUSIONS: The FDA approval of AGENT DCB marks a significant milestone in the management of ISR, offering a promising alternative to conventional interventions. With its ability to deliver antiproliferative therapy while avoiding the complications associated with permanent stents, DCB may revolutionize PCI strategies in the United States. Further studies assessing the long-term impact of this technology, as well as its application in broader patient populations, will be essential to solidify its role in clinical practice.